NASDAQ:AKUS

Akouos Competitors

$14.09
-0.51 (-3.49 %)
(As of 04/21/2021 12:37 PM ET)
Add
Compare
Today's Range
$14.05
Now: $14.09
$14.81
50-Day Range
$13.47
MA: $16.92
$21.04
52-Week Range
$13.16
Now: $14.09
$30.67
Volume2,521 shs
Average Volume211,251 shs
Market Capitalization$484.72 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Akouos (NASDAQ:AKUS) Vs. NGM, AMRN, RVNC, AXSM, FGEN, and IGMS

Should you be buying AKUS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Akouos, including NGM Biopharmaceuticals (NGM), Amarin (AMRN), Revance Therapeutics (RVNC), Axsome Therapeutics (AXSM), FibroGen (FGEN), and IGM Biosciences (IGMS).

Akouos (NASDAQ:AKUS) and NGM Biopharmaceuticals (NASDAQ:NGM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Akouos and NGM Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkouosN/AN/AN/A
NGM Biopharmaceuticals-91.64%-29.47%-25.58%

Institutional & Insider Ownership

88.7% of Akouos shares are owned by institutional investors. Comparatively, 49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. 50.4% of NGM Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and price targets for Akouos and NGM Biopharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akouos01302.75
NGM Biopharmaceuticals00523.29

Akouos presently has a consensus target price of $31.6667, suggesting a potential upside of 124.75%. NGM Biopharmaceuticals has a consensus target price of $39.1111, suggesting a potential upside of 47.48%. Given Akouos' higher probable upside, research analysts clearly believe Akouos is more favorable than NGM Biopharmaceuticals.

Valuation & Earnings

This table compares Akouos and NGM Biopharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkouosN/AN/AN/AN/AN/A
NGM Biopharmaceuticals$103.54 million19.70$-42,790,000.00($0.85)-31.29

Akouos has higher earnings, but lower revenue than NGM Biopharmaceuticals.

Akouos (NASDAQ:AKUS) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Akouos and Amarin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkouosN/AN/AN/A
Amarin-2.69%-2.70%-1.72%

Institutional and Insider Ownership

88.7% of Akouos shares are owned by institutional investors. Comparatively, 37.8% of Amarin shares are owned by institutional investors. 2.8% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Akouos and Amarin's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkouosN/AN/AN/AN/AN/A
Amarin$429.76 million4.61$-22,650,000.00($0.07)-72.00

Akouos has higher earnings, but lower revenue than Amarin.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Akouos and Amarin, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akouos01302.75
Amarin03802.73

Akouos presently has a consensus target price of $31.6667, suggesting a potential upside of 124.75%. Amarin has a consensus target price of $11.1818, suggesting a potential upside of 121.86%. Given Akouos' stronger consensus rating and higher probable upside, analysts plainly believe Akouos is more favorable than Amarin.

Summary

Akouos beats Amarin on 6 of the 9 factors compared between the two stocks.

Akouos (NASDAQ:AKUS) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Valuation & Earnings

This table compares Akouos and Revance Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkouosN/AN/AN/AN/AN/A
Revance Therapeutics$410,000.004,761.77$-159,430,000.00($3.67)-7.45

Akouos has higher earnings, but lower revenue than Revance Therapeutics.

Insider and Institutional Ownership

88.7% of Akouos shares are held by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are held by institutional investors. 4.8% of Revance Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Akouos and Revance Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akouos01302.75
Revance Therapeutics00403.00

Akouos presently has a consensus target price of $31.6667, suggesting a potential upside of 124.75%. Revance Therapeutics has a consensus target price of $37.75, suggesting a potential upside of 38.03%. Given Akouos' higher possible upside, equities research analysts clearly believe Akouos is more favorable than Revance Therapeutics.

Profitability

This table compares Akouos and Revance Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkouosN/AN/AN/A
Revance Therapeutics-5,818.87%-85.72%-44.85%

Summary

Akouos beats Revance Therapeutics on 5 of the 9 factors compared between the two stocks.

Axsome Therapeutics (NASDAQ:AXSM) and Akouos (NASDAQ:AKUS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Earnings & Valuation

This table compares Axsome Therapeutics and Akouos' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-26.03
AkouosN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Axsome Therapeutics and Akouos, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axsome Therapeutics101002.82
Akouos01302.75

Axsome Therapeutics currently has a consensus price target of $152.6667, suggesting a potential upside of 191.79%. Akouos has a consensus price target of $31.6667, suggesting a potential upside of 124.75%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than Akouos.

Institutional & Insider Ownership

63.6% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 88.7% of Akouos shares are held by institutional investors. 26.0% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Axsome Therapeutics and Akouos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axsome TherapeuticsN/A-62.33%-47.87%
AkouosN/AN/AN/A

Summary

Axsome Therapeutics beats Akouos on 4 of the 7 factors compared between the two stocks.

Akouos (NASDAQ:AKUS) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Akouos and FibroGen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akouos01302.75
FibroGen15202.13

Akouos currently has a consensus price target of $31.6667, suggesting a potential upside of 124.75%. FibroGen has a consensus price target of $45.8333, suggesting a potential upside of 127.01%. Given FibroGen's higher probable upside, analysts plainly believe FibroGen is more favorable than Akouos.

Earnings and Valuation

This table compares Akouos and FibroGen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkouosN/AN/AN/AN/AN/A
FibroGen$256.58 million7.21$-76,970,000.00($0.89)-22.56

Akouos has higher earnings, but lower revenue than FibroGen.

Profitability

This table compares Akouos and FibroGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkouosN/AN/AN/A
FibroGen-191.78%-48.19%-27.72%

Insider & Institutional Ownership

88.7% of Akouos shares are held by institutional investors. Comparatively, 75.1% of FibroGen shares are held by institutional investors. 3.4% of FibroGen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Akouos beats FibroGen on 6 of the 9 factors compared between the two stocks.

IGM Biosciences (NASDAQ:IGMS) and Akouos (NASDAQ:AKUS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares IGM Biosciences and Akouos' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-12.07
AkouosN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for IGM Biosciences and Akouos, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IGM Biosciences01602.86
Akouos01302.75

IGM Biosciences presently has a consensus target price of $98.8750, indicating a potential upside of 70.36%. Akouos has a consensus target price of $31.6667, indicating a potential upside of 124.75%. Given Akouos' higher probable upside, analysts clearly believe Akouos is more favorable than IGM Biosciences.

Insider and Institutional Ownership

47.6% of IGM Biosciences shares are owned by institutional investors. Comparatively, 88.7% of Akouos shares are owned by institutional investors. 79.3% of IGM Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares IGM Biosciences and Akouos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IGM BiosciencesN/A-33.30%-30.28%
AkouosN/AN/AN/A

Summary

Akouos beats IGM Biosciences on 4 of the 7 factors compared between the two stocks.


Akouos Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.60-3.0%$1.98 billion$103.54 million-20.00
Amarin logo
AMRN
Amarin
1.6$5.04-1.8%$1.95 billion$429.76 million-100.78
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.35-2.0%$1.91 billion$410,000.00-5.95
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.32-3.2%$1.89 billionN/A-19.45Unusual Options Activity
News Coverage
FibroGen logo
FGEN
FibroGen
1.8$20.08-1.3%$1.87 billion$256.58 million-7.69
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$57.94-0.1%$1.86 billionN/A-24.66
Kura Oncology logo
KURA
Kura Oncology
1.6$27.63-1.2%$1.85 billionN/A-16.95News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$25.10-0.8%$1.81 billion$26.87 million-13.14Analyst Report
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$19.73-0.7%$1.79 billion$34.51 million-16.86
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18
MORF
Morphic
1.3$57.34-5.4%$1.76 billion$16.98 million-36.76Insider Selling
Gap Up
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.72-0.6%$1.72 billion$428.41 million15.54Analyst Upgrade
Unusual Options Activity
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.69-0.4%$1.70 billion$1.63 billion13.88
Generation Bio logo
GBIO
Generation Bio
1.8$30.42-1.1%$1.70 billionN/A0.00Gap Up
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.75-0.2%$1.63 billion$145.97 million-7.19
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.49-2.5%$1.62 billion$392.76 million13.07Analyst Upgrade
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.97-5.9%$1.62 billionN/A-6.75Analyst Downgrade
Increase in Short Interest
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.24-1.2%$1.58 billion$2.34 million-9.85
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.82-1.4%$1.56 billionN/A0.00
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.5$35.33-6.0%$1.55 billionN/A0.00Analyst Upgrade
News Coverage
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.58-1.4%$1.52 billion$175.34 million-15.05Insider Selling
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.19-2.6%$1.51 billion$320,000.00-8.29
uniQure logo
QURE
uniQure
1.7$31.80-2.2%$1.46 billion$7.28 million-8.43Unusual Options Activity
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.44-1.6%$1.46 billion$82.27 million-18.15
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$29.48-2.8%$1.44 billionN/A-3.19Analyst Upgrade
Gap Up
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$61.95-1.1%$1.43 billionN/A0.00
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$22.19-0.5%$1.42 billion$73.41 million-4.69News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$40.38-1.5%$1.40 billionN/A0.00
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.01-2.3%$1.40 billionN/A0.00Gap Down
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$31.89-0.5%$1.38 billion$6.20 million-13.99
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$27.89-1.4%$1.37 billion$19.89 million-13.16
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.39-3.4%$1.37 billion$4.23 million-20.29Analyst Report
Increase in Short Interest
News Coverage
Gap Down
OLMA
Olema Pharmaceuticals
1.6$34.86-3.8%$1.35 billionN/A0.00Gap Up
Endo International logo
ENDP
Endo International
1.5$5.75-2.1%$1.30 billion$2.91 billion-8.46
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.35-6.4%$1.28 billionN/A-143.13Analyst Downgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$29.51-0.0%$1.23 billionN/A0.00Analyst Report
Insider Selling
Zymeworks logo
ZYME
Zymeworks
1.8$27.25-2.8%$1.22 billion$29.54 million-7.23News Coverage
Innoviva logo
INVA
Innoviva
1.4$12.04-0.5%$1.21 billion$261.02 million6.14News Coverage
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$32.95-2.0%$1.18 billionN/A0.00Analyst Upgrade
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$31.17-2.5%$1.18 billionN/A0.00Analyst Report
Insider Selling
Gap Up
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$27.53-3.3%$1.17 billion$230,000.00-12.80
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.91-4.5%$1.16 billion$59.70 million-199.10
Omeros logo
OMER
Omeros
1.2$19.03-2.5%$1.15 billion$111.81 million-8.00
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.81-1.1%$1.14 billionN/A-17.12
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.01-0.4%$1.14 billionN/A-8.76Analyst Report
Increase in Short Interest
News Coverage
Kronos Bio logo
KRON
Kronos Bio
1.7$20.94-4.1%$1.13 billionN/A0.00Insider Selling
News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.31-3.5%$1.12 billion$4.23 million-8.55
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$36.82-3.9%$1.11 billionN/A-2.63
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.01-0.6%$1.10 billionN/A-6.76Upcoming Earnings
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.